Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.17 GBX | +0.69% | +2.99% | -3.14% |
Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 82.8M 105M |
---|---|---|---|---|---|
Net income 2024 * | -14M -17.73M | Net income 2025 * | -14M -17.73M | EV / Sales 2024 * | - |
Net Debt 2024 * | 3.88M 4.91M | Net Debt 2025 * | 14.94M 18.92M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.61
x | P/E ratio 2025 * |
-6.68
x | Employees | 51 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.52% |
1 week | +2.28% | ||
Current month | +13.23% | ||
1 month | +5.76% | ||
3 months | -10.22% | ||
6 months | -20.78% | ||
Current year | -3.81% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
Director of Finance/CFO | 38 | 23-08-28 | |
Fayaz Master
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 65 | 23-01-31 | |
Ursula Ney
BRD | Director/Board Member | 72 | 19-10-22 |
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 10.17 | +0.69% | 104 867 |
24-05-16 | 10.1 | 0.00% | 284,226 |
24-05-15 | 10.1 | 0.00% | 37,102 |
24-05-14 | 10.1 | +2.28% | 327,257 |
24-05-13 | 9.875 | 0.00% | 371,718 |
Delayed Quote London S.E., May 17, 2024 at 02:59 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.81% | 105M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+50.18% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- SCLP Stock